Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Moderate Buy” by Analysts

Arcus Biosciences, Inc. (NYSE:RCUS) has been assigned an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $36.40.

A number of equities analysts have recently issued reports on the stock. Morgan Stanley increased their price target on shares of Arcus Biosciences from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Monday, May 11th. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Friday, July 17th. Truist Financial began coverage on shares of Arcus Biosciences in a report on Monday, May 18th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Lifesci Capital initiated coverage on shares of Arcus Biosciences in a research report on Thursday, June 4th. They set an “outperform” rating and a $46.00 price target for the company.

Insider Activity at Arcus Biosciences

In related news, President Juan C. Jaen sold 48,502 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $30.05, for a total value of $1,457,485.10. Following the completion of the transaction, the president directly owned 842,307 shares of the company’s stock, valued at $25,311,325.35. This trade represents a 5.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Alexander Azoy sold 2,562 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $25.77, for a total value of $66,022.74. Following the sale, the chief accounting officer owned 39,581 shares in the company, valued at approximately $1,020,002.37. The trade was a 6.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 110,325 shares of company stock valued at $3,174,319 in the last ninety days. Corporate insiders own 7.60% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in RCUS. Hantz Financial Services Inc. grew its stake in Arcus Biosciences by 121.9% in the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arcus Biosciences in the fourth quarter valued at about $39,000. KBC Group NV purchased a new stake in shares of Arcus Biosciences in the first quarter valued at about $50,000. Strs Ohio purchased a new stake in shares of Arcus Biosciences in the first quarter valued at about $67,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after purchasing an additional 5,476 shares during the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Trading Down 1.7%

NYSE:RCUS opened at $27.70 on Tuesday. The stock has a fifty day moving average price of $27.09 and a two-hundred day moving average price of $24.11. The stock has a market capitalization of $3.48 billion, a price-to-earnings ratio of -8.71 and a beta of 0.80. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.04 and a current ratio of 4.04. Arcus Biosciences has a 1 year low of $8.88 and a 1 year high of $31.74.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The business had revenue of $17.00 million during the quarter, compared to analyst estimates of $29.48 million. During the same period last year, the business posted ($1.14) EPS. Arcus Biosciences’s revenue was down 39.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Arcus Biosciences will post -3.66 earnings per share for the current fiscal year.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.